Menu Search
Equities

Cybin Inc

R7E1:BER

Cybin Inc

Actions
  • Price (EUR)0.24
  • Today's Change-0.006 / -2.44%
  • Shares traded0.00
  • 1 Year change-62.63%
  • Beta--
Data delayed at least 15 minutes, as of Jun 01 2023 20:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company's CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-51.87m
  • Incorporated2016
  • Employees50.00
  • Location
    Cybin Inc100 King Street West, Suite 5600TORONTO M5X 1C9CanadaCAN
  • Phone+1 (604) 806-0626
  • Fax+1 (604) 806-0626
  • Websitehttps://www.cybin.com
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.